Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines announced that detailed results from its pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma patients, will be presented at the 2026 ASCO Annual Meeting. The topline data showed statistically significant and cli…